Cargando…

Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug

Recent research on antiretroviral treatment (ART) for HIV suggests that integrase strand transfer inhibitors (INSTIs) cause faster weight gain compared to other drug classes. Here, we investigated changes in body mass index (BMI) and obesity prevalence after treatment initiation and corresponding di...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantazis, Nikos, Papastamopoulos, Vasilios, Antoniadou, Anastasia, Adamis, Georgios, Paparizos, Vasilios, Metallidis, Simeon, Sambatakou, Helen, Psichogiou, Mina, Chini, Maria, Chrysos, Georgios, Panagopoulos, Periklis, Sipsas, Nikolaos V., Barbunakis, Emmanouil, Gogos, Charalambos, Touloumi, Giota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415309/
https://www.ncbi.nlm.nih.gov/pubmed/36016299
http://dx.doi.org/10.3390/v14081677
_version_ 1784776200359510016
author Pantazis, Nikos
Papastamopoulos, Vasilios
Antoniadou, Anastasia
Adamis, Georgios
Paparizos, Vasilios
Metallidis, Simeon
Sambatakou, Helen
Psichogiou, Mina
Chini, Maria
Chrysos, Georgios
Panagopoulos, Periklis
Sipsas, Nikolaos V.
Barbunakis, Emmanouil
Gogos, Charalambos
Touloumi, Giota
author_facet Pantazis, Nikos
Papastamopoulos, Vasilios
Antoniadou, Anastasia
Adamis, Georgios
Paparizos, Vasilios
Metallidis, Simeon
Sambatakou, Helen
Psichogiou, Mina
Chini, Maria
Chrysos, Georgios
Panagopoulos, Periklis
Sipsas, Nikolaos V.
Barbunakis, Emmanouil
Gogos, Charalambos
Touloumi, Giota
author_sort Pantazis, Nikos
collection PubMed
description Recent research on antiretroviral treatment (ART) for HIV suggests that integrase strand transfer inhibitors (INSTIs) cause faster weight gain compared to other drug classes. Here, we investigated changes in body mass index (BMI) and obesity prevalence after treatment initiation and corresponding differences between drug classes. Data were derived from a large collaborative cohort in Greece. Included individuals were adults who started ART, in or after 2010, while previously ART naïve and achieved virologic response within the first year of ART. Data were analysed using mixed fractional polynomial models. INSTI regimens led to the more pronounced BMI increases, followed by boosted PI and NNRTI based regimens. Individuals with normal initial BMI are expected to gain 6 kg with an INSTI regimen compared to 4 kg with a boosted PI and less than 3 kg with a NNRTI regimen after four years of treatment. Prevalence of obesity was 5.7% at ART initiation and 12.2%, 14.2% and 18.1% after four years of treatment with NNRTIs, PIs, and INSTIs, respectively. Dolutegravir or Raltegravir were associated with marginally faster BMI increase compared to Elvitegravir. INSTIs are associated with faster weight gain. INSTIs’ increased risk of treatment emergent obesity and, possibly, weight-related co-morbidities should be judged against their improved efficacy and tolerability but increased clinical attention is required.
format Online
Article
Text
id pubmed-9415309
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94153092022-08-27 Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug Pantazis, Nikos Papastamopoulos, Vasilios Antoniadou, Anastasia Adamis, Georgios Paparizos, Vasilios Metallidis, Simeon Sambatakou, Helen Psichogiou, Mina Chini, Maria Chrysos, Georgios Panagopoulos, Periklis Sipsas, Nikolaos V. Barbunakis, Emmanouil Gogos, Charalambos Touloumi, Giota Viruses Article Recent research on antiretroviral treatment (ART) for HIV suggests that integrase strand transfer inhibitors (INSTIs) cause faster weight gain compared to other drug classes. Here, we investigated changes in body mass index (BMI) and obesity prevalence after treatment initiation and corresponding differences between drug classes. Data were derived from a large collaborative cohort in Greece. Included individuals were adults who started ART, in or after 2010, while previously ART naïve and achieved virologic response within the first year of ART. Data were analysed using mixed fractional polynomial models. INSTI regimens led to the more pronounced BMI increases, followed by boosted PI and NNRTI based regimens. Individuals with normal initial BMI are expected to gain 6 kg with an INSTI regimen compared to 4 kg with a boosted PI and less than 3 kg with a NNRTI regimen after four years of treatment. Prevalence of obesity was 5.7% at ART initiation and 12.2%, 14.2% and 18.1% after four years of treatment with NNRTIs, PIs, and INSTIs, respectively. Dolutegravir or Raltegravir were associated with marginally faster BMI increase compared to Elvitegravir. INSTIs are associated with faster weight gain. INSTIs’ increased risk of treatment emergent obesity and, possibly, weight-related co-morbidities should be judged against their improved efficacy and tolerability but increased clinical attention is required. MDPI 2022-07-29 /pmc/articles/PMC9415309/ /pubmed/36016299 http://dx.doi.org/10.3390/v14081677 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pantazis, Nikos
Papastamopoulos, Vasilios
Antoniadou, Anastasia
Adamis, Georgios
Paparizos, Vasilios
Metallidis, Simeon
Sambatakou, Helen
Psichogiou, Mina
Chini, Maria
Chrysos, Georgios
Panagopoulos, Periklis
Sipsas, Nikolaos V.
Barbunakis, Emmanouil
Gogos, Charalambos
Touloumi, Giota
Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug
title Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug
title_full Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug
title_fullStr Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug
title_full_unstemmed Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug
title_short Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug
title_sort changes in body mass index after initiation of antiretroviral treatment: differences by class of core drug
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415309/
https://www.ncbi.nlm.nih.gov/pubmed/36016299
http://dx.doi.org/10.3390/v14081677
work_keys_str_mv AT pantazisnikos changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT papastamopoulosvasilios changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT antoniadouanastasia changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT adamisgeorgios changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT paparizosvasilios changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT metallidissimeon changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT sambatakouhelen changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT psichogioumina changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT chinimaria changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT chrysosgeorgios changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT panagopoulosperiklis changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT sipsasnikolaosv changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT barbunakisemmanouil changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT gogoscharalambos changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug
AT touloumigiota changesinbodymassindexafterinitiationofantiretroviraltreatmentdifferencesbyclassofcoredrug